Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 6702 entries
Sorted by: Best Match Show Resources per page
Occupational risk of bladder cancer among Iranian male workers.

Urology annals

Aminian O, Saburi A, Mohseni H, Akbari H, Chavoshi F, Akbari H.
PMID: 24833825
Urol Ann. 2014 Apr;6(2):135-8. doi: 10.4103/0974-7796.130643.

BACKGROUND: Approximately 5-10% of human cancers are thought to be caused by occupational exposure to carcinogens. Compare to other cancers, bladder cancer is most strongly linked to occupational exposure to chemical toxins. This study has been performed to understand...

Cite
Aminian O, Saburi A, Mohseni H, et al. Occupational risk of bladder cancer among Iranian male workers. Urol Ann. 2014;6(2):135-8doi: 10.4103/0974-7796.130643.
Aminian, O., Saburi, A., Mohseni, H., Akbari, H., Chavoshi, F., & Akbari, H. (2014). Occupational risk of bladder cancer among Iranian male workers. Urology annals, 6(2), 135-8. https://doi.org/10.4103/0974-7796.130643
Aminian, Omid, et al. "Occupational risk of bladder cancer among Iranian male workers." Urology annals vol. 6,2 (2014): 135-8. doi: https://doi.org/10.4103/0974-7796.130643
Aminian O, Saburi A, Mohseni H, Akbari H, Chavoshi F, Akbari H. Occupational risk of bladder cancer among Iranian male workers. Urol Ann. 2014 Apr;6(2):135-8. doi: 10.4103/0974-7796.130643. PMID: 24833825; PMCID: PMC4021653.
Copy Download .nbib Format: NLM
The effect of preoperative clinical variables on the 30- and 90-day morbidity and mortality after radical cystectomy: A single-centre study.

Arab journal of urology

Mursi K, ElFayoumy H, Saad I, Tawakol A, Badawy H.
PMID: 26558074
Arab J Urol. 2013 Jun;11(2):152-8. doi: 10.1016/j.aju.2013.03.006. Epub 2013 May 03.

OBJECTIVE: To analyse the effect of preoperative clinical variables and comorbidity on the early, late and cumulative 90-day morbidity and mortality rates, as well as hospital re-admissions, after radical cystectomy (RC), in one centre.PATIENTS AND METHODS: All patients undergoing...

Cite
Mursi K, ElFayoumy H, Saad I, et al. The effect of preoperative clinical variables on the 30- and 90-day morbidity and mortality after radical cystectomy: A single-centre study. Arab J Urol. 2013;11(2):152-8doi: 10.1016/j.aju.2013.03.006.
Mursi, K., ElFayoumy, H., Saad, I., Tawakol, A., & Badawy, H. (2013). The effect of preoperative clinical variables on the 30- and 90-day morbidity and mortality after radical cystectomy: A single-centre study. Arab journal of urology, 11(2), 152-8. https://doi.org/10.1016/j.aju.2013.03.006
Mursi, Khaled, et al. "The effect of preoperative clinical variables on the 30- and 90-day morbidity and mortality after radical cystectomy: A single-centre study." Arab journal of urology vol. 11,2 (2013): 152-8. doi: https://doi.org/10.1016/j.aju.2013.03.006
Mursi K, ElFayoumy H, Saad I, Tawakol A, Badawy H. The effect of preoperative clinical variables on the 30- and 90-day morbidity and mortality after radical cystectomy: A single-centre study. Arab J Urol. 2013 Jun;11(2):152-8. doi: 10.1016/j.aju.2013.03.006. Epub 2013 May 03. PMID: 26558074; PMCID: PMC4442999.
Copy Download .nbib Format: NLM
MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C.

Experimental and therapeutic medicine

He X, Ping J, Wen D.
PMID: 28966690
Exp Ther Med. 2017 Oct;14(4):3253-3258. doi: 10.3892/etm.2017.4908. Epub 2017 Aug 08.

The present study aimed to investigate the expression of microRNA (miRNA or miR)-186 in tumor tissue, blood and urine from patients with bladder cancer. The mechanism by which miR-186 regulates the invasion and metastasis of bladder cancer was also...

Cite
He X, Ping J, Wen D. MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C. Exp Ther Med. 2017;14(4):3253-3258doi: 10.3892/etm.2017.4908.
He, X., Ping, J., & Wen, D. (2017). MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C. Experimental and therapeutic medicine, 14(4), 3253-3258. https://doi.org/10.3892/etm.2017.4908
He, Xuefeng, et al. "MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C." Experimental and therapeutic medicine vol. 14,4 (2017): 3253-3258. doi: https://doi.org/10.3892/etm.2017.4908
He X, Ping J, Wen D. MicroRNA-186 regulates the invasion and metastasis of bladder cancer via vascular endothelial growth factor C. Exp Ther Med. 2017 Oct;14(4):3253-3258. doi: 10.3892/etm.2017.4908. Epub 2017 Aug 08. PMID: 28966690; PMCID: PMC5613196.
Copy Download .nbib Format: NLM
LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma.

Oncotarget

Liu Z, Zhang H.
PMID: 28969069
Oncotarget. 2017 Jul 26;8(38):64273-64282. doi: 10.18632/oncotarget.19604. eCollection 2017 Sep 08.

Bladder cancer (BC) is the most lethal malignant cancer of the genitourinary system, and bladder urothelial carcinoma (BUC) is the most common type of BC. The long non-coding RNA (lncRNA) plasmacytoma variant translocation 1 (PVT1) is overexpressed in several...

Cite
Liu Z, Zhang H. LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. Oncotarget. 2017;8(38):64273-64282doi: 10.18632/oncotarget.19604.
Liu, Z., & Zhang, H. (2017). LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. Oncotarget, 8(38), 64273-64282. https://doi.org/10.18632/oncotarget.19604
Liu, Zhongyuan, and Zhang, Hui. "LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma." Oncotarget vol. 8,38 (2017): 64273-64282. doi: https://doi.org/10.18632/oncotarget.19604
Liu Z, Zhang H. LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. Oncotarget. 2017 Jul 26;8(38):64273-64282. doi: 10.18632/oncotarget.19604. eCollection 2017 Sep 08. PMID: 28969069; PMCID: PMC5610001.
Copy Download .nbib Format: NLM
Spinal Metastasis of Unknown Primary Accompanied by Neurologic Deficit or Vertebral Instability.

World neurosurgery

Aycan A, Celik S, Kuyumcu F, Akyol ME, Arslan M, Dogan E, Arslan H.
PMID: 28951274
World Neurosurg. 2018 Jan;109:e33-e42. doi: 10.1016/j.wneu.2017.09.099. Epub 2017 Sep 23.

BACKGROUND AND OBJECTIVE: Spinal bone metastases are common. They are mostly localized to the lumbar, thoracic, and cervical spine. The most common primaries to result in spinal metastases include lung, breast, and prostate carcinomas in adults as opposed to...

Cite
Aycan A, Celik S, Kuyumcu F, et al. Spinal Metastasis of Unknown Primary Accompanied by Neurologic Deficit or Vertebral Instability. World Neurosurg. 2017;109:e33-e42doi: 10.1016/j.wneu.2017.09.099.
Aycan, A., Celik, S., Kuyumcu, F., Akyol, M. E., Arslan, M., Dogan, E., & Arslan, H. (2018). Spinal Metastasis of Unknown Primary Accompanied by Neurologic Deficit or Vertebral Instability. World neurosurgery, 109e33-e42. https://doi.org/10.1016/j.wneu.2017.09.099
Aycan, Abdurrahman, et al. "Spinal Metastasis of Unknown Primary Accompanied by Neurologic Deficit or Vertebral Instability." World neurosurgery vol. 109 (2018): e33-e42. doi: https://doi.org/10.1016/j.wneu.2017.09.099
Aycan A, Celik S, Kuyumcu F, Akyol ME, Arslan M, Dogan E, Arslan H. Spinal Metastasis of Unknown Primary Accompanied by Neurologic Deficit or Vertebral Instability. World Neurosurg. 2018 Jan;109:e33-e42. doi: 10.1016/j.wneu.2017.09.099. Epub 2017 Sep 23. PMID: 28951274.
Copy Download .nbib Format: NLM
Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells.

Oncology letters

Horikawa Y, Watanabe M, Sadahira T, Ariyoshi Y, Kobayashi Y, Araki M, Wada K, Ochiai K, Li SA, Nasu Y.
PMID: 28927069
Oncol Lett. 2017 Sep;14(3):3223-3228. doi: 10.3892/ol.2017.6548. Epub 2017 Jul 08.

Our group previously developed an adenoviral vector encoding the REIC/Dkk-3 gene (Ad-REIC), a tumor suppressor, for cancer gene therapy. The Ad-REIC agent induces apoptosis and inhibits invasion in a number of cancer cell lines; however, the molecular mechanisms underlying...

Cite
Horikawa Y, Watanabe M, Sadahira T, et al. Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells. Oncol Lett. 2017;14(3):3223-3228doi: 10.3892/ol.2017.6548.
Horikawa, Y., Watanabe, M., Sadahira, T., Ariyoshi, Y., Kobayashi, Y., Araki, M., Wada, K., Ochiai, K., Li, S. A., & Nasu, Y. (2017). Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells. Oncology letters, 14(3), 3223-3228. https://doi.org/10.3892/ol.2017.6548
Horikawa, Yuhei, et al. "Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells." Oncology letters vol. 14,3 (2017): 3223-3228. doi: https://doi.org/10.3892/ol.2017.6548
Horikawa Y, Watanabe M, Sadahira T, Ariyoshi Y, Kobayashi Y, Araki M, Wada K, Ochiai K, Li SA, Nasu Y. Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells. Oncol Lett. 2017 Sep;14(3):3223-3228. doi: 10.3892/ol.2017.6548. Epub 2017 Jul 08. PMID: 28927069; PMCID: PMC5588074.
Copy Download .nbib Format: NLM
Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.

BMC research notes

Vallo S, Michaelis M, Gust KM, Black PC, Rothweiler F, Kvasnicka HM, Blaheta RA, Brandt MP, Wezel F, Haferkamp A, Cinatl J.
PMID: 27677700
BMC Res Notes. 2016 Sep 27;9(1):454. doi: 10.1186/s13104-016-2256-3.

BACKGROUND: Systemic chemotherapy with gemcitabine and cisplatin is standard of care for patients with metastatic urothelial bladder cancer. However, resistance formation is common after initial response. The protein Src is known as a proto-oncogene, which is overexpressed in various...

Cite
Vallo S, Michaelis M, Gust KM, et al. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC Res Notes. 2016;9(1):454doi: 10.1186/s13104-016-2256-3.
Vallo, S., Michaelis, M., Gust, K. M., Black, P. C., Rothweiler, F., Kvasnicka, H. M., Blaheta, R. A., Brandt, M. P., Wezel, F., Haferkamp, A., & Cinatl, J. (2016). Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC research notes, 9(1), 454. https://doi.org/10.1186/s13104-016-2256-3
Vallo, Stefan, et al. "Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts." BMC research notes vol. 9,1 (2016): 454. doi: https://doi.org/10.1186/s13104-016-2256-3
Vallo S, Michaelis M, Gust KM, Black PC, Rothweiler F, Kvasnicka HM, Blaheta RA, Brandt MP, Wezel F, Haferkamp A, Cinatl J. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC Res Notes. 2016 Sep 27;9(1):454. doi: 10.1186/s13104-016-2256-3. PMID: 27677700; PMCID: PMC5039786.
Copy Download .nbib Format: NLM
Identification of hMex-3A and its effect on human bladder cancer cell proliferation.

Oncotarget

Huang Y, Fang C, Shi JW, Wen Y, Liu D.
PMID: 28977858
Oncotarget. 2017 May 22;8(37):61215-61225. doi: 10.18632/oncotarget.18050. eCollection 2017 Sep 22.

In this study,

Cite
Huang Y, Fang C, Shi JW, et al. Identification of hMex-3A and its effect on human bladder cancer cell proliferation. Oncotarget. 2017;8(37):61215-61225doi: 10.18632/oncotarget.18050.
Huang, Y., Fang, C., Shi, J. W., Wen, Y., & Liu, D. (2017). Identification of hMex-3A and its effect on human bladder cancer cell proliferation. Oncotarget, 8(37), 61215-61225. https://doi.org/10.18632/oncotarget.18050
Huang, Ying, et al. "Identification of hMex-3A and its effect on human bladder cancer cell proliferation." Oncotarget vol. 8,37 (2017): 61215-61225. doi: https://doi.org/10.18632/oncotarget.18050
Huang Y, Fang C, Shi JW, Wen Y, Liu D. Identification of hMex-3A and its effect on human bladder cancer cell proliferation. Oncotarget. 2017 May 22;8(37):61215-61225. doi: 10.18632/oncotarget.18050. eCollection 2017 Sep 22. PMID: 28977858; PMCID: PMC5617418.
Copy Download .nbib Format: NLM
Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies.

Oncotarget

Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A.
PMID: 28978063
Oncotarget. 2017 Jun 28;8(40):67684-67695. doi: 10.18632/oncotarget.18804. eCollection 2017 Sep 15.

Expression of ESR1, PGR, HER2 and Ki67 is important for risk stratification and therapy in breast cancer. Hormone receptor expression can also be found in MIBC, reflecting luminal and basal subtypes of breast cancer. Thus the purpose was to...

Cite
Breyer J, Wirtz RM, Otto W, et al. Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. Oncotarget. 2017;8(40):67684-67695doi: 10.18632/oncotarget.18804.
Breyer, J., Wirtz, R. M., Otto, W., Laible, M., Schlombs, K., Erben, P., Kriegmair, M. C., Stoehr, R., Eidt, S., Denzinger, S., Burger, M., & Hartmann, A. (2017). Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. Oncotarget, 8(40), 67684-67695. https://doi.org/10.18632/oncotarget.18804
Breyer, Johannes, et al. "Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies." Oncotarget vol. 8,40 (2017): 67684-67695. doi: https://doi.org/10.18632/oncotarget.18804
Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A. Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. Oncotarget. 2017 Jun 28;8(40):67684-67695. doi: 10.18632/oncotarget.18804. eCollection 2017 Sep 15. PMID: 28978063; PMCID: PMC5620203.
Copy Download .nbib Format: NLM
Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer.

Oncotarget

Wang X, Cui MM, Xu Y, Liu L, Niu Y, Liu T, Liu ZP, Wang RT, Yu KJ.
PMID: 28978101
Oncotarget. 2017 Jul 12;8(40):68115-68122. doi: 10.18632/oncotarget.19242. eCollection 2017 Sep 15.

BACKGROUND: Altered mean platelet volume (MPV) is implicated in a wide range of cancers. However, the prognostic role of MPV in muscle-invasive bladder cancer (MIBC) remains largely unknown. The purpose of this study was to elucidate the predictive significance...

Cite
Wang X, Cui MM, Xu Y, et al. Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer. Oncotarget. 2017;8(40):68115-68122doi: 10.18632/oncotarget.19242.
Wang, X., Cui, M. M., Xu, Y., Liu, L., Niu, Y., Liu, T., Liu, Z. P., Wang, R. T., & Yu, K. J. (2017). Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer. Oncotarget, 8(40), 68115-68122. https://doi.org/10.18632/oncotarget.19242
Wang, Xin, et al. "Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer." Oncotarget vol. 8,40 (2017): 68115-68122. doi: https://doi.org/10.18632/oncotarget.19242
Wang X, Cui MM, Xu Y, Liu L, Niu Y, Liu T, Liu ZP, Wang RT, Yu KJ. Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer. Oncotarget. 2017 Jul 12;8(40):68115-68122. doi: 10.18632/oncotarget.19242. eCollection 2017 Sep 15. PMID: 28978101; PMCID: PMC5620241.
Copy Download .nbib Format: NLM
Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B.

Oncotarget

Yang J, Liu Y, He A, Liu Y, Wu J, Liao X, Lv Z, Wang F, Mei H.
PMID: 28978151
Oncotarget. 2017 Aug 03;8(40):68721-68729. doi: 10.18632/oncotarget.19878. eCollection 2017 Sep 15.

BACKGROUND AND OBJECTIVES: Hsa-miR-429 is increased in bladder cancer. Its roles in bladder cancer are poorly understood.METHODS: The expression levels of hsa-miR-429 and cyclin-dependent kinase inhibitor 2B (CDKN2B) were determined using Real-Time qPCR in a total of 50 patients...

Cite
Yang J, Liu Y, He A, et al. Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B. Oncotarget. 2017;8(40):68721-68729doi: 10.18632/oncotarget.19878.
Yang, J., Liu, Y., He, A., Liu, Y., Wu, J., Liao, X., Lv, Z., Wang, F., & Mei, H. (2017). Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B. Oncotarget, 8(40), 68721-68729. https://doi.org/10.18632/oncotarget.19878
Yang, Jiangeng, et al. "Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B." Oncotarget vol. 8,40 (2017): 68721-68729. doi: https://doi.org/10.18632/oncotarget.19878
Yang J, Liu Y, He A, Liu Y, Wu J, Liao X, Lv Z, Wang F, Mei H. Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B. Oncotarget. 2017 Aug 03;8(40):68721-68729. doi: 10.18632/oncotarget.19878. eCollection 2017 Sep 15. PMID: 28978151; PMCID: PMC5620291.
Copy Download .nbib Format: NLM
MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1.

American journal of cancer research

Yang X, Shi L, Yi C, Yang Y, Chang L, Song D.
PMID: 28861329
Am J Cancer Res. 2017 Aug 01;7(8):1738-1753. eCollection 2017.

Current evidence indicates that microRNAs are widely down-regulated in various tumors including colorectal carcinoma, liver cancer and lung cancer, and function as tumor suppressors through inhibiting cancer cell growth, invasion and migration. Here, we demonstrated that miR-210-3p level was...

Cite
Yang X, Shi L, Yi C, et al. MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1. Am J Cancer Res. 2017;7(8):1738-1753
Yang, X., Shi, L., Yi, C., Yang, Y., Chang, L., & Song, D. (2017). MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1. American journal of cancer research, 7(8), 1738-1753.
Yang, Xiaoming, et al. "MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1." American journal of cancer research vol. 7,8 (2017): 1738-1753.
Yang X, Shi L, Yi C, Yang Y, Chang L, Song D. MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1. Am J Cancer Res. 2017 Aug 01;7(8):1738-1753. eCollection 2017. PMID: 28861329; PMCID: PMC5574945.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 6702 entries